Sponsor of the Day:
Jerkmate
https://www.biopharmadive.com/news/biotech-ipo-performance-q1-2026/815879/
Biotech IPOs stayed at slow pace, but grew larger in the first quarter of 2026 | BioPharma Dive
The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing what’s been observed over a...
2026 biopharma diveslow pacefirst quarterbiotechipos
https://www.biopharmadive.com/news/fda-approval-decisions-watch-2026/808684/
5 FDA decisions to watch in the second quarter of 2026 | BioPharma Dive
2026 biopharma divefda decisionssecond quarter5watch
https://www.biopharmadive.com/press-release/20260403-bryet-us-inc-to-present-ml-016-preclinical-efficacy-data-at-aacr-2026/
BrYet US, Inc. to Present ML-016 Preclinical Efficacy Data at AACR 2026 | BioPharma Dive
2026 biopharma diveus incpreclinical efficacypresentml